$PDLI Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PDL BIOPHARMA, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PDL BIOPHARMA, INC.. Get notifications about new insider transactions in PDL BIOPHARMA, INC. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 04 2021 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.50 | 6,325,213 | 15,813,033 | 23,783,273 | 17.5 M to 23.8 M (+36.23 %) |
Dec 31 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Sell | S | 2.74 | 20,000 | 54,800 | 1,387 | 21.4 K to 1.4 K (-93.51 %) |
Dec 29 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.69 | 268,600 | 722,534 | 17,458,060 | 17.2 M to 17.5 M (+1.56 %) |
Dec 29 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.70 | 235,000 | 634,500 | 17,189,460 | 17 M to 17.2 M (+1.39 %) |
Dec 29 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.65 | 128,000 | 339,200 | 16,954,460 | 16.8 M to 17 M (+0.76 %) |
Dec 23 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.60 | 485,000 | 1,261,000 | 16,826,460 | 16.3 M to 16.8 M (+2.97 %) |
Dec 23 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.59 | 850,000 | 2,201,500 | 16,341,460 | 15.5 M to 16.3 M (+5.49 %) |
Dec 23 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.63 | 230,000 | 604,900 | 15,491,460 | 15.3 M to 15.5 M (+1.51 %) |
Dec 22 2020 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | Director | Sell | S | 2.61 | 277,934 | 724,574 | 200,000 | 477.9 K to 200 K (-58.15 %) |
Dec 22 2020 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | Director | Sell | S | 2.62 | 50,000 | 131,200 | 477,934 | 527.9 K to 477.9 K (-9.47 %) |
Dec 18 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.61 | 398,000 | 1,038,780 | 15,261,460 | 14.9 M to 15.3 M (+2.68 %) |
Dec 18 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.58 | 1,350,000 | 3,483,000 | 14,863,460 | 13.5 M to 14.9 M (+9.99 %) |
Dec 17 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Sell | S | 2.56 | 200,000 | 512,000 | 405,559 | 605.6 K to 405.6 K (-33.03 %) |
Dec 17 2020 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President and CEO | Sell | S | 2.60 | 500,000 | 1,300,000 | 734,921 | 1.2 M to 734.9 K (-40.49 %) |
Dec 17 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Sell | S | 2.56 | 200,000 | 512,000 | 405,559 | 605.6 K to 405.6 K (-33.03 %) |
Dec 17 2020 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President and CEO | Sell | S | 2.60 | 500,000 | 1,300,000 | 734,921 | 1.2 M to 734.9 K (-40.49 %) |
Dec 17 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Sell | S | 2.68 | 75,000 | 201,000 | 21,387 | 96.4 K to 21.4 K (-77.81 %) |
Dec 17 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Sell | S | 2.68 | 75,000 | 201,000 | 21,387 | 96.4 K to 21.4 K (-77.81 %) |
Dec 15 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.59 | 1,000,000 | 2,590,000 | 13,513,460 | 12.5 M to 13.5 M (+7.99 %) |
Dec 15 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.62 | 640,000 | 1,676,800 | 12,513,460 | 11.9 M to 12.5 M (+5.39 %) |
Dec 15 2020 | PDLI | PDL BIOPHARMA, INC ... | Silver Point Capital L.P. | 10% Owner | Buy | P | 2.45 | 450,000 | 1,102,500 | 11,873,460 | 11.4 M to 11.9 M (+3.94 %) |
Dec 04 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Sell | D | 0.00 | 11,544 | 0 | 605,559 | 617.1 K to 605.6 K (-1.87 %) |
Dec 04 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Sell | S | 2.52 | 75,000 | 189,000 | 30,337 | 105.3 K to 30.3 K (-71.20 %) |
Dec 04 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Sell | D | 0.00 | 11,544 | 0 | 605,559 | 617.1 K to 605.6 K (-1.87 %) |
Dec 04 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Sell | S | 2.52 | 75,000 | 189,000 | 30,337 | 105.3 K to 30.3 K (-71.20 %) |
Nov 19 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Sell | S | 2.39 | 50,000 | 119,500 | 95,337 | 145.3 K to 95.3 K (-34.40 %) |
Nov 19 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Sell | S | 2.40 | 100,000 | 240,000 | 145,337 | 245.3 K to 145.3 K (-40.76 %) |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | Hernday Natasha | Director | Option Exercise | A | 3.63 | 118,671 | 430,776 | 118,671 | |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | Hernday Natasha | Director | Grant | A | 0.00 | 25,826 | 0 | 75,826 | 50 K to 75.8 K (+51.65 %) |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | Director | Option Exercise | A | 3.63 | 118,671 | 430,776 | 118,671 | |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | Director | Grant | A | 0.00 | 25,826 | 0 | 527,934 | 502.1 K to 527.9 K (+5.14 %) |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | Bazaar Alan Lee | Director | Option Exercise | A | 3.63 | 118,671 | 430,776 | 118,671 | |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | Bazaar Alan Lee | Director | Grant | A | 0.00 | 25,826 | 0 | 33,435 | 7.6 K to 33.4 K (+339.41 %) |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Option Exercise | A | 3.63 | 118,671 | 430,776 | 118,671 | |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Grant | A | 0.00 | 25,826 | 0 | 245,337 | 219.5 K to 245.3 K (+11.77 %) |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | O'Farrell Elizabeth G. | Director | Option Exercise | A | 3.63 | 118,671 | 430,776 | 118,671 | |
Aug 24 2020 | PDLI | PDL BIOPHARMA, INC ... | O'Farrell Elizabeth G. | Director | Grant | A | 0.00 | 25,826 | 0 | 89,117 | 63.3 K to 89.1 K (+40.81 %) |
May 26 2020 | PDLI | PDL BIOPHARMA, INC ... | PDL BIOPHARMA, INC. | 10% Owner | Sell | J | 0.00 | 13,333,334 | 0 | 0 | 13.3 M to 0 (-100.00 %) |
Apr 21 2020 | PDLI | PDL BIOPHARMA, INC ... | Bazaar Alan Lee | Director | Option Exercise | A | 3.07 | 37,080 | 113,836 | 37,080 | |
Apr 21 2020 | PDLI | PDL BIOPHARMA, INC ... | Bazaar Alan Lee | Director | Grant | A | 0.00 | 7,609 | 0 | 7,609 | 0 to 7.6 K |
Apr 21 2020 | PDLI | PDL BIOPHARMA, INC ... | Bazaar Alan Lee | Director | Option Exercise | A | 3.07 | 37,080 | 113,836 | 37,080 | |
Apr 21 2020 | PDLI | PDL BIOPHARMA, INC ... | Bazaar Alan Lee | Director | Grant | A | 0.00 | 7,609 | 0 | 7,609 | 0 to 7.6 K |
Apr 07 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Payment of Exercise | F | 3.33 | 2,686 | 8,944 | 617,103 | 619.8 K to 617.1 K (-0.43 %) |
Apr 07 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Payment of Exercise | F | 3.43 | 1,240 | 4,253 | 619,789 | 621 K to 619.8 K (-0.20 %) |
Apr 07 2020 | PDLI | PDL BIOPHARMA, INC ... | Imbrogno Edward | VP Finance, CAO and ... | Payment of Exercise | F | 3.51 | 82,488 | 289,533 | 232,077 | 314.6 K to 232.1 K (-26.22 %) |
Apr 07 2020 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President and CEO | Payment of Exercise | F | 3.51 | 672,505 | 2,360,493 | 1,234,921 | 1.9 M to 1.2 M (-35.26 %) |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Imbrogno Edward | VP Finance, CAO and ... | Grant | A | 0.00 | 292,208 | 0 | 314,565 | 22.4 K to 314.6 K (+1,307.01 %) |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Grant | A | 0.00 | 422,078 | 0 | 621,029 | 199 K to 621 K (+212.15 %) |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President and CEO | Grant | A | 0.00 | 1,233,766 | 0 | 1,907,426 | 673.7 K to 1.9 M (+183.14 %) |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Jene Jill M. | VP, Business Develo ... | Grant | A | 0.00 | 194,805 | 0 | 194,805 | 0 to 194.8 K |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Imbrogno Edward | VP Finance, CAO and ... | Grant | A | 0.00 | 292,208 | 0 | 314,565 | 22.4 K to 314.6 K (+1,307.01 %) |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Grant | A | 0.00 | 422,078 | 0 | 621,029 | 199 K to 621 K (+212.15 %) |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President and CEO | Grant | A | 0.00 | 1,233,766 | 0 | 1,907,426 | 673.7 K to 1.9 M (+183.14 %) |
Jan 10 2020 | PDLI | PDL BIOPHARMA, INC ... | Jene Jill M. | VP, Business Develo ... | Grant | A | 0.00 | 194,805 | 0 | 194,805 | 0 to 194.8 K |
Jul 08 2019 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Yanai Shlomo | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Hernday Natasha | Director | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | SELICK HAROLD E | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | O'Farrell Elizabeth G. | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Sandman Paul W | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Yanai Shlomo | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Hernday Natasha | Director | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | SELICK HAROLD E | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | O'Farrell Elizabeth G. | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Sandman Paul W | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
Jun 10 2019 | PDLI | PDL BIOPHARMA, INC ... | PDL BIOPHARMA, INC. | 10% Owner | Option Exercise | A | 6.38 | 1,666,667 | 10,633,335 | 1,666,667 | |
Jun 10 2019 | PDLI | PDL BIOPHARMA, INC ... | PDL BIOPHARMA, INC. | 10% Owner | Buy | P | 4.50 | 6,666,667 | 30,000,002 | 13,333,334 | 6.7 M to 13.3 M (+100.00 %) |
Apr 01 2019 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Option Exercise | A | 3.72 | 628,930 | 2,339,620 | 628,930 | |
Apr 01 2019 | PDLI | PDL BIOPHARMA, INC ... | Jene Jill M. | VP, Business Develo ... | Option Exercise | A | 3.72 | 377,358 | 1,403,772 | 377,358 | |
Apr 01 2019 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President and CEO | Option Exercise | A | 3.72 | 2,450,000 | 9,114,000 | 2,450,000 | |
Apr 01 2019 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President and CEO | Grant | A | 3.72 | 431,317 | 1,604,499 | 653,902 | 222.6 K to 653.9 K (+193.78 %) |
Apr 01 2019 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Option Exercise | A | 3.72 | 817,610 | 3,041,509 | 817,610 | |
Jan 09 2019 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | CEO | Sell | D | 0.00 | 123,449 | 0 | 502,108 | 625.6 K to 502.1 K (-19.73 %) |
Dec 28 2018 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President | Payment of Exercise | F | 3.02 | 17,615 | 53,197 | 222,585 | 240.2 K to 222.6 K (-7.33 %) |
Dec 28 2018 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Sell | D | 0.00 | 226,442 | 0 | 225,029 | 451.5 K to 225 K (-50.16 %) |
Dec 28 2018 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Payment of Exercise | F | 3.02 | 3,553 | 10,730 | 451,471 | 455 K to 451.5 K (-0.78 %) |
Dec 28 2018 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Sell | D | 0.00 | 228,255 | 0 | 198,951 | 427.2 K to 199 K (-53.43 %) |
Dec 28 2018 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Payment of Exercise | F | 3.02 | 3,581 | 10,815 | 427,206 | 430.8 K to 427.2 K (-0.83 %) |
Dec 28 2018 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | CEO | Sell | D | 0.00 | 627,228 | 0 | 625,557 | 1.3 M to 625.6 K (-50.07 %) |
Sep 27 2018 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President | Option Exercise | A | 2.52 | 1,479,944 | 3,729,459 | 1,479,944 | |
Sep 27 2018 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Option Exercise | A | 2.52 | 339,623 | 855,850 | 339,623 | |
Sep 27 2018 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Option Exercise | A | 2.52 | 339,678 | 855,989 | 339,678 | |
Sep 27 2018 | PDLI | PDL BIOPHARMA, INC ... | Jene Jill M. | VP, Business Develo ... | Option Exercise | A | 2.52 | 377,358 | 950,942 | 377,358 | |
Jun 25 2018 | PDLI | PDL BIOPHARMA, INC ... | O'Farrell Elizabeth G. | Director | Grant | A | 2.37 | 63,291 | 150,000 | 63,291 | 0 to 63.3 K |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Option Exercise | A | 2.94 | 700,500 | 2,059,470 | 700,500 | |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Option Exercise | A | 2.94 | 694,900 | 2,043,006 | 694,900 | |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | CEO | Option Exercise | A | 2.94 | 1,922,100 | 5,650,974 | 1,922,100 | |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Lindell Jody S | Director | Grant | A | 2.76 | 54,348 | 150,000 | 256,174 | 201.8 K to 256.2 K (+26.93 %) |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 2.76 | 54,348 | 150,000 | 214,563 | 160.2 K to 214.6 K (+33.92 %) |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Yanai Shlomo | Director | Grant | A | 2.76 | 54,348 | 150,000 | 54,348 | 0 to 54.3 K |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 2.76 | 54,348 | 150,000 | 214,190 | 159.8 K to 214.2 K (+34.00 %) |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | SELICK HAROLD E | Director | Grant | A | 2.76 | 54,348 | 150,000 | 256,828 | 202.5 K to 256.8 K (+26.84 %) |
Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Sandman Paul W | Director | Grant | A | 2.76 | 54,348 | 150,000 | 262,800 | 208.5 K to 262.8 K (+26.07 %) |
Dec 19 2017 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | CEO | Sell | D | 0.00 | 151,678 | 0 | 1,252,785 | 1.4 M to 1.3 M (-10.80 %) |
Dec 19 2017 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Sell | D | 0.00 | 17,818 | 0 | 455,024 | 472.8 K to 455 K (-3.77 %) |
Dec 19 2017 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Sell | D | 0.00 | 17,959 | 0 | 430,787 | 448.7 K to 430.8 K (-4.00 %) |
Dec 19 2017 | PDLI | PDL BIOPHARMA, INC ... | Pietzke Steffen | VP, Finance and CAO | Sell | D | 0.00 | 5,513 | 0 | 139,587 | 145.1 K to 139.6 K (-3.80 %) |
Sep 13 2017 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President | Option Exercise | A | 3.21 | 961,000 | 3,084,810 | 961,000 | |
Sep 13 2017 | PDLI | PDL BIOPHARMA, INC ... | Monnet Dominique | President | Grant | A | 0.00 | 240,200 | 0 | 240,200 | 0 to 240.2 K |
Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 2.47 | 60,729 | 150,001 | 160,215 | 99.5 K to 160.2 K (+61.04 %) |
Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | Lindell Jody S | Director | Grant | A | 2.47 | 60,729 | 150,001 | 201,826 | 141.1 K to 201.8 K (+43.04 %) |
Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Grant | A | 2.47 | 60,729 | 150,001 | 165,163 | 104.4 K to 165.2 K (+58.15 %) |
Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | SELICK HAROLD E | Director | Grant | A | 2.47 | 60,729 | 150,001 | 202,480 | 141.8 K to 202.5 K (+42.84 %) |
Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | Sandman Paul W | Director | Grant | A | 2.47 | 60,729 | 150,001 | 208,452 | 147.7 K to 208.5 K (+41.11 %) |
Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 2.47 | 60,729 | 150,001 | 159,842 | 99.1 K to 159.8 K (+61.27 %) |
Mar 27 2017 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 1.98 | 5,000 | 9,890 | 472,842 | 467.8 K to 472.8 K (+1.07 %) |
Mar 27 2017 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 1.98 | 5,000 | 9,884 | 467,842 | 462.8 K to 467.8 K (+1.08 %) |
Mar 27 2017 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 1.98 | 10,000 | 19,757 | 462,842 | 452.8 K to 462.8 K (+2.21 %) |
Mar 27 2017 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 1.98 | 350 | 691 | 452,842 | 452.5 K to 452.8 K (+0.08 %) |
Mar 27 2017 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 1.97 | 4,650 | 9,179 | 452,492 | 447.8 K to 452.5 K (+1.04 %) |
Mar 07 2017 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Grant | A | 2.04 | 212,669 | 433,845 | 447,842 | 235.2 K to 447.8 K (+90.43 %) |
Mar 07 2017 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Grant | A | 2.04 | 214,372 | 437,319 | 448,746 | 234.4 K to 448.7 K (+91.47 %) |
Mar 07 2017 | PDLI | PDL BIOPHARMA, INC ... | Pietzke Steffen | Controller and CAO | Grant | A | 2.04 | 98,039 | 200,000 | 145,100 | 47.1 K to 145.1 K (+208.32 %) |
Mar 07 2017 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | President, CEO | Grant | A | 2.04 | 588,235 | 1,199,999 | 1,404,463 | 816.2 K to 1.4 M (+72.07 %) |
Mar 07 2017 | PDLI | PDL BIOPHARMA, INC ... | Hart Danny J Jr. | VP Business Develop ... | Grant | A | 2.04 | 199,019 | 405,999 | 387,236 | 188.2 K to 387.2 K (+105.74 %) |
Dec 15 2016 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Sell | D | 0.00 | 1,919 | 0 | 235,173 | 237.1 K to 235.2 K (-0.81 %) |
Dec 15 2016 | PDLI | PDL BIOPHARMA, INC ... | Hart Danny J Jr. | VP Business Develop ... | Sell | D | 0.00 | 1,844 | 0 | 188,217 | 190.1 K to 188.2 K (-0.97 %) |
Dec 15 2016 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Sell | D | 0.00 | 1,935 | 0 | 234,374 | 236.3 K to 234.4 K (-0.82 %) |
Dec 15 2016 | PDLI | PDL BIOPHARMA, INC ... | Pietzke Steffen | Controller and CAO | Sell | D | 0.00 | 663 | 0 | 47,061 | 47.7 K to 47.1 K (-1.39 %) |
Dec 15 2016 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | President, CEO | Sell | D | 0.00 | 5,168 | 0 | 816,228 | 821.4 K to 816.2 K (-0.63 %) |
Aug 10 2016 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 3.00 | 5,000 | 14,980 | 237,092 | 232.1 K to 237.1 K (+2.15 %) |
Aug 10 2016 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 3.00 | 5,000 | 14,980 | 237,092 | 232.1 K to 237.1 K (+2.15 %) |
Aug 10 2016 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 2.99 | 5,000 | 14,970 | 232,092 | 227.1 K to 232.1 K (+2.20 %) |
Aug 10 2016 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 2.99 | 5,000 | 14,970 | 232,092 | 227.1 K to 232.1 K (+2.20 %) |
Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 3.52 | 71,023 | 250,001 | 99,113 | 28.1 K to 99.1 K (+252.84 %) |
Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 3.52 | 71,023 | 250,001 | 99,486 | 28.5 K to 99.5 K (+249.53 %) |
Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | GRYSKA DAVID W | Director | Grant | A | 3.52 | 71,023 | 250,001 | 104,434 | 33.4 K to 104.4 K (+212.57 %) |
Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | Lindell Jody S | Director | Grant | A | 3.52 | 71,023 | 250,001 | 141,097 | 70.1 K to 141.1 K (+101.35 %) |
Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | Sandman Paul W | Director | Grant | A | 3.52 | 71,023 | 250,001 | 147,723 | 76.7 K to 147.7 K (+92.60 %) |
Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | SELICK HAROLD E | Director | Grant | A | 3.52 | 71,023 | 250,001 | 141,751 | 70.7 K to 141.8 K (+100.42 %) |
Jan 28 2016 | PDLI | PDL BIOPHARMA, INC ... | Pietzke Steffen | Controller and CAO | Grant | A | 3.22 | 31,135 | 100,255 | 47,724 | 16.6 K to 47.7 K (+187.68 %) |
Jan 28 2016 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Grant | A | 3.22 | 101,860 | 327,989 | 236,309 | 134.4 K to 236.3 K (+75.76 %) |
Jan 28 2016 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Grant | A | 3.22 | 101,051 | 325,384 | 227,092 | 126 K to 227.1 K (+80.17 %) |
Jan 28 2016 | PDLI | PDL BIOPHARMA, INC ... | Hart Danny J Jr. | VP Business Develop ... | Grant | A | 3.22 | 94,565 | 304,499 | 190,061 | 95.5 K to 190.1 K (+99.03 %) |
Jan 28 2016 | PDLI | PDL BIOPHARMA, INC ... | MCLAUGHLIN JOHN PETER | President, CEO | Grant | A | 3.22 | 403,727 | 1,300,001 | 821,396 | 417.7 K to 821.4 K (+96.66 %) |
Dec 16 2015 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 3.64 | 5,000 | 18,200 | 126,041 | 121 K to 126 K (+4.13 %) |
Dec 16 2015 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 3.42 | 10,000 | 34,245 | 121,041 | 111 K to 121 K (+9.01 %) |
Dec 07 2015 | PDLI | PDL BIOPHARMA, INC ... | Pietzke Steffen | Controller and CAO | Buy | P | 3.64 | 20,590 | 74,931 | 20,590 | 0 to 20.6 K |
Oct 05 2015 | PDLI | PDL BIOPHARMA, INC ... | Stone Christopher Lewis | VP, Gen. Counsel & ... | Grant | A | 4.95 | 15,291 | 75,690 | 155,764 | 140.5 K to 155.8 K (+10.89 %) |
Oct 05 2015 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Grant | A | 4.95 | 15,169 | 75,087 | 111,041 | 95.9 K to 111 K (+15.82 %) |
Oct 05 2015 | PDLI | PDL BIOPHARMA, INC ... | Pietzke Steffen | Controller and CAO | Grant | A | 4.95 | 1,841 | 9,113 | 16,589 | 14.7 K to 16.6 K (+12.48 %) |
Oct 05 2015 | PDLI | PDL BIOPHARMA, INC ... | Hart Danny J Jr. | VP Business Develop ... | Grant | A | 4.95 | 17,576 | 87,001 | 95,496 | 77.9 K to 95.5 K (+22.56 %) |
Sep 16 2015 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 5.34 | 28,090 | 150,001 | 28,090 | 0 to 28.1 K |
Sep 08 2015 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 5.27 | 28,463 | 150,000 | 28,463 | 0 to 28.5 K |
Aug 17 2015 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 5.80 | 300 | 1,740 | 95,872 | 95.6 K to 95.9 K (+0.31 %) |
Aug 17 2015 | PDLI | PDL BIOPHARMA, INC ... | GARCIA PETER S | Vice President, CFO | Buy | P | 5.79 | 7,300 | 42,267 | 95,572 | 88.3 K to 95.6 K (+8.27 %) |